Lefkos Middleton, MD, FRCP
Lefkos Middleton holds the chair of Neuroepidemiology and Ageing Research at the School of Public Health, Imperial College London. He studied medicine and trained in Neurology at the Université Louis Pasteur, in Strasbourg (France) and then became Fellow at the Neurological Institute of New York, Presbyterian Hospital and Assistant Professor of Columbia University. Following the award to him of a major US grant in 1988, he founded and became first Chairman of Cyprus Institute of Neurology. In his initial research in Cyprus led to the identification and mapping of the Vitamin E Deficiency Ataxia (AVED), rare forms of Hereditary Motor Neuropathy and a Congenital Myasthenia Syndrome due to mutations in acetylcholine receptor ε-subunit gene.
In 1999, he joined the GlaxoWellcome Genetics Research Directorate, based in London and, following the merger with SKB, he was invited to create a new R&D Department, termed Translational Medicine and Genetics (TMG). TMG was a new R&D function that combined medical genetics, imaging, biomarkers and experimental medicine. In this role, he led the development of the Imaging Centre at the Imperial College Hammersmith Hospital (now known as Imanova) and the Experimental Medicine Unit at Addenbrooke's Hospital, University of Cambridge.
In 2007, he was appointed Professor of Neurology and head of the Department of Neuroscience and Mental Health at Imperial College London (ICL). He then moved to the newly formed ICL School of Public Health and established the Neuroepidemiology and Ageing Research Unit to expand his activities in prevention studies and trials in the prodromal and early stages of late-onset dementias and Alzheimer's disease. His Unit now includes three Faculty members as well as 74 medical, research and administrative staff.
He is, currently, the principal investigator of the Chariot register [a cohort of ~30,000 healthy volunteers for Alzheimer's disease (AD) prevention studies, in West London], the industry sponsored Chariot PRO biomarker- enriched observational study on the natural history of the early stages of AD and the Funnel study for early AD. He is the Chief UK Investigator of three clinical trials in AD and the principal investigator of a study of gene-environment interactions in Parkinson's disease and related dementias. He was the principal investigator of the Parkinson's UK Brain Bank, held at Imperial College London, during the years 2009-2014.
He served, in years 2005-2008, as Council member of the Medical Research Council (MRC) and also served as a non - executive Director of the West London Mental (2010-2014). In 2014, he was appointed by the Department of Health as the Clinical Lead and Chair of the International Clinical & Technology Expert Group (CTEG) for Integrated Development, formed as part of the Global Dementia Initiative, initiated by HM Government at the Global Dementia Summit, hosted by the British Prime Minister in December 2013. He has authored / co-authored 157 publications. He is also the Chair of the "Caring and Ageing Re-imagine for Europe" (CARE) European consortium. CARE, formed of major academic and industry institutions across Europe and in the US, is an activity within the European Institute of Innovation and Technology for Health (EIT-Health). The main objectives of CARE are to develop an e-based School for Carers (on-line course with formal certification) and to increase awareness of the impact of the demographic explosion resulting from the increasing aging of the world population, including dementia and other age-related diseases, their prevention and management.
In 1999, he joined the GlaxoWellcome Genetics Research Directorate, based in London and, following the merger with SKB, he was invited to create a new R&D Department, termed Translational Medicine and Genetics (TMG). TMG was a new R&D function that combined medical genetics, imaging, biomarkers and experimental medicine. In this role, he led the development of the Imaging Centre at the Imperial College Hammersmith Hospital (now known as Imanova) and the Experimental Medicine Unit at Addenbrooke's Hospital, University of Cambridge.
In 2007, he was appointed Professor of Neurology and head of the Department of Neuroscience and Mental Health at Imperial College London (ICL). He then moved to the newly formed ICL School of Public Health and established the Neuroepidemiology and Ageing Research Unit to expand his activities in prevention studies and trials in the prodromal and early stages of late-onset dementias and Alzheimer's disease. His Unit now includes three Faculty members as well as 74 medical, research and administrative staff.
He is, currently, the principal investigator of the Chariot register [a cohort of ~30,000 healthy volunteers for Alzheimer's disease (AD) prevention studies, in West London], the industry sponsored Chariot PRO biomarker- enriched observational study on the natural history of the early stages of AD and the Funnel study for early AD. He is the Chief UK Investigator of three clinical trials in AD and the principal investigator of a study of gene-environment interactions in Parkinson's disease and related dementias. He was the principal investigator of the Parkinson's UK Brain Bank, held at Imperial College London, during the years 2009-2014.
He served, in years 2005-2008, as Council member of the Medical Research Council (MRC) and also served as a non - executive Director of the West London Mental (2010-2014). In 2014, he was appointed by the Department of Health as the Clinical Lead and Chair of the International Clinical & Technology Expert Group (CTEG) for Integrated Development, formed as part of the Global Dementia Initiative, initiated by HM Government at the Global Dementia Summit, hosted by the British Prime Minister in December 2013. He has authored / co-authored 157 publications. He is also the Chair of the "Caring and Ageing Re-imagine for Europe" (CARE) European consortium. CARE, formed of major academic and industry institutions across Europe and in the US, is an activity within the European Institute of Innovation and Technology for Health (EIT-Health). The main objectives of CARE are to develop an e-based School for Carers (on-line course with formal certification) and to increase awareness of the impact of the demographic explosion resulting from the increasing aging of the world population, including dementia and other age-related diseases, their prevention and management.